adefovir dipivoxil (hepsera) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
The potential antiviral effect of adefovir, an acyclic nucleoside phosphonate analog of 2′-deoxyadenosine monophosphate, was first studied by Holý and De Clercq in 1980s. Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. Oral adefovir dipivoxil is effective and generally well tolerated in HBeAg-positive and -negative patients chronically infected with wild-type or lamivudine-resistant HBV.   NCATS

Chemistry

  • SMILES: NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O
  • InChIKey: SUPKOOSCJHTBAH-UHFFFAOYSA-N
  • Mol. Mass: 273.1857
  • ALogP: -0.44
  • ChEMBL Molecules:
    adefovir  
    adefovir dipivoxil  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Missing data
  • Pro Drug: Yes

Drug Pricing (per unit)

Australia

$11.0671

United States

$15.3357 - $31.6210
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

9-(2-((-bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine | 9-(2-phosphonomethoxyethyl)adenine | 9-(2-phosphonylmethoxyethyl)adenine | 9-pmea | adefovir | adefovir depivoxil | adefovir di(pivaloyloxymethyl) ester | adefovir dipivoxil | adefovir pivoxil | bis-pom pmea | gs-0393 | gs-0840 | gs 840 | hepsera | preveon

Organizations (83)

Research & Development (81)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (3)


 

Hepatitis B (approved 2002)

Hepatitis B, Chronic

Leukemia, Myeloid, Acute

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Carcinoma, Hepatocellular (Phase 4)

Chronic Disease (Phase 3)

Cytomegalovirus Infections (Phase 3)

Drug Interactions (Phase 1)

Drugs, Investigational (Phase 4)

Fibrosis (Phase 4)

Healthy Volunteers (Phase 4)

Hepatitis (Phase 2)

Hepatitis B (Phase 4)

Hepatitis B, Chronic ()

Hepatitis B virus (Phase 2)

Hepatitis C (Phase 2)

Hepatitis, Chronic (Phase 3)

HIV Infections (Phase 3)

Liver Cirrhosis (Phase 1/Phase 2)

Liver Failure (Phase 1/Phase 2)

Liver Transplantation (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 112
  • # of Trial Organizations: 81

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue